AT1 3.85% 2.5¢ atomo diagnostics limited

Access Bio's newly developed blood-based IgG/IgM diagnostic test...

  1. 407 Posts.
    lightbulb Created with Sketch. 46
    Access Bio's newly developed blood-based IgG/IgM diagnostic test detects antibodiesproduced in response to infection by COVID-19. Access Bio’s standard test kit format received an Emergency Use Authorisation1 (EUA) by the US Food & Drug Administration(FDA) on 24 July 2020

    Access Bio already have approval for their standard device but yet they are still wanting to uses Atomo's device so even if it was the same type of test there is still demand.
 
watchlist Created with Sketch. Add AT1 (ASX) to my watchlist
(20min delay)
Last
2.5¢
Change
-0.001(3.85%)
Mkt cap ! $15.98M
Open High Low Value Volume
2.6¢ 2.6¢ 2.5¢ $15.57K 604.4K

Buyers (Bids)

No. Vol. Price($)
4 277067 2.5¢
 

Sellers (Offers)

Price($) Vol. No.
2.7¢ 18145 1
View Market Depth
Last trade - 15.57pm 28/06/2024 (20 minute delay) ?
AT1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.